Panelists discuss recent phase 3 trial results of a novel oral agent for idiopathic pulmonary fibrosis (IPF) and progressive ...

Growth at the Edges: Top 40 Vendors Reflect Evolving Market Dynamics By Rita E. Garwood A surge of independent growth and a reshuffling at the top define Monitor’s 2025 Vendor Top 40, with Wells Fargo ...

The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.